Patents by Inventor Reza Mazhari

Reza Mazhari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230257363
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Application
    Filed: September 23, 2022
    Publication date: August 17, 2023
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Patent number: 11479542
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: October 25, 2022
    Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Publication number: 20210107892
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Application
    Filed: May 27, 2020
    Publication date: April 15, 2021
    Inventors: Reza Mazhari, Ojelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Publication number: 20200231553
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 23, 2020
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
  • Patent number: 10710976
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 14, 2020
    Assignees: Cerecor Inc., Merck Sharp & Dohme Corp.
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Patent number: 10570101
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: February 25, 2020
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
  • Publication number: 20190275042
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 12, 2019
    Applicant: Rexahn Pharmaceuticals, Inc.
    Inventors: Young Bok Lee, Deog Joong Kim, Godefridus J. Peters, Reza Mazhari, Dzjemma Sarkisjan
  • Publication number: 20190177299
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 13, 2019
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Patent number: 10278971
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: May 7, 2019
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young Bok Lee, Deog Joong Kim, Godefridus J. Peters, Reza Mazhari, Dzjemma Sarkisjan
  • Patent number: 10202363
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 12, 2019
    Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Publication number: 20180290985
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 6, 2018
    Publication date: October 11, 2018
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
  • Patent number: 9969698
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 15, 2018
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
  • Publication number: 20180021338
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Application
    Filed: August 22, 2017
    Publication date: January 25, 2018
    Applicant: Rexahn Pharmaceuticals, Inc.
    Inventors: Young Bok Lee, Deog Joong Kim, Godefridus J. Peters, Reza Mazhari, Dzjemma Sarkisjan
  • Publication number: 20170369469
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Applicants: Cerecor, Inc., Merck Sharp & Dohme Corp.
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • Patent number: 9782410
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 10, 2017
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
  • Publication number: 20170066726
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 2, 2016
    Publication date: March 9, 2017
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog Joong Kim, Young Bok Lee, Reza Mazhari, Daniel Edward Emrich
  • Publication number: 20170014411
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Application
    Filed: June 9, 2016
    Publication date: January 19, 2017
    Applicant: Rexahn Pharmaceuticals, Inc.
    Inventors: Young Bok Lee, Deog Joong Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
  • Publication number: 20160081951
    Abstract: The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 24, 2015
    Publication date: March 24, 2016
    Inventors: Reza Mazhari, Vincent J. Kalish
  • Publication number: 20130274342
    Abstract: Compositions, methods of making compositions and methods of treating cough are described herein. In some embodiments, the compositions are lozenges comprising memantine and an alkalinizing agent.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 17, 2013
    Applicant: Cerecor, Inc.
    Inventors: Mark GINSKI, Blake PATERSON, Reza MAZHARI, Djelila MEZAACHE
  • Publication number: 20110160200
    Abstract: The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 30, 2011
    Applicant: CARDIOXYL PHARMACEUTICALS, INC.
    Inventors: Reza Mazhari, Vincent J. Kalish